atypical chronic myeloid leukemia, BCR-ABL negative
Showing 1 - 25 of >10,000
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid
Active, not recruiting
- Acute Myeloid Leukemia
- +9 more
- Carboplatin
- +3 more
-
Los Angeles, California
- +5 more
Jan 27, 2023
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Rochester (Hyperbaric oxygen)
Recruiting
- Acute Myeloid Leukemia
- +6 more
- Hyperbaric oxygen
-
Rochester, New YorkWilmot Cancer Institute, University of Rochester
May 16, 2022
Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia Trial in Toronto (Observational)
Recruiting
- Primary Myelofibrosis
- +9 more
- Observational
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Apr 11, 2022
Myelodysplastic Syndrome, Myeloproliferative Tumors, Chronic Myelomonocytic Leukemia Trial in United States (other, drug,
Recruiting
- Myelodysplastic Syndrome
- +4 more
- Geriatric assessment (GA) pre-transplant
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Aug 24, 2022
Myeloproliferative Tumor, Chronic Phase Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia Trial in San Francisco (Online
Recruiting
- Myeloproliferative Neoplasm
- +2 more
- Online Mindfulness Meditation
- Internet-Based Webinars
-
San Francisco, CaliforniaUniversity of California San Francisco
Aug 9, 2022
Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Recruiting
- Chronic Phase Chronic Myelogenous Leukemia
- +3 more
- Dasatinib
- Decitabine and Cedazuridine
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Neutrophilic Leukemia Trial in United States (Laboratory Biomarker
Completed
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Chronic Neutrophilic Leukemia
- Laboratory Biomarker Analysis
- +3 more
-
Palo Alto, California
- +6 more
Oct 22, 2020
Asciminib RMP Study
Not yet recruiting
- Chronic Myeloid Leukemia
- Asciminib
- (no location specified)
Jul 5, 2023
Outcomes in Chronic Myeloid Leukaemia
Completed
- Chronic Myeloid Leukaemia
-
York, United KingdomHaematological Malignancy Research Network
Jun 7, 2023
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +6 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2022
Chronic Myelogenous Leukemia - Chronic Phase Trial in Avignon (APN and medical management, Medical management, Quality of life
Not yet recruiting
- Chronic Myelogenous Leukemia - Chronic Phase
- APN and medical management
- +3 more
-
Avignon, Provence-Alpes-Côte d'Azur, FranceCentre Hospitalier d'Avignon, Hôpital Henri Duffaut
Oct 13, 2023
CML, Chronic Phase, CML, Accelerated Phase Trial in Wuhan (HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion))
Recruiting
- CML, Chronic Phase
- CML, Accelerated Phase
- HS-10382(Part 1: Dose escalation)
- HS-10382(Part 2: Dose expansion)
-
Wuhan, Hubei, ChinaUnion Hospital affiliated to Tongji Medical College of Huazhong
Jan 12, 2023
Real-World Usage of Asciminib Among Chronic Myeloid Leukemia in
Completed
- Chronic Myeloid Leukemia
-
East Hanover, New JerseyNovartis
Nov 20, 2023
Chronic Myeloid Leukemia, BCR/ABL-Positive Trial in Taipei
Not yet recruiting
- Chronic Myeloid Leukemia, BCR/ABL-Positive
-
Taipei, TaiwanNational Taiwan University Hospital
Jul 24, 2022
Chronic Myeloid Leukemia Any Phase Treated With Ponatinib at Any
Active, not recruiting
- Chronic Myeloid Leukemia, Chronic Phase
-
Jena, GermanyUniversity Hospital Jena
Jan 17, 2023
According to Molecular Identification at Diagnosis
Not yet recruiting
- Chronic Myeloid Leukemia
- Next Generation Sequencing (DNA and RNA)
- (no location specified)
Oct 28, 2022
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in
Recruiting
- Acute Biphenotypic Leukemia
- +13 more
- Cladribine
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jan 19, 2023
Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Trial in Houston (Asciminib)
Recruiting
- Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
-
Houston, TexasM D Anderson Cancer Center
Feb 1, 2022
B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- ABL001
- +2 more
-
Chicago, Illinois
- +5 more
Dec 27, 2021
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic
Recruiting
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
- Dasatinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 24, 2022
Ponatinib in CML Patients in Chronic Phase
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- Therapeutic drug monitoring
- Molecular Response
-
Cagliari, Italy
- +4 more
Nov 3, 2023
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic
Recruiting
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 15, 2022
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia Trial (Miltenyi CliniMACS Prodigy ®
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +6 more
- Miltenyi CliniMACS Prodigy ® system
- (no location specified)
Mar 23, 2023
"Peripheral Blood Dipeptidylpeptidase IV Positive Leukemic Stem
Not yet recruiting
- Chronic Myeloid Leukemia, Chronic Phase
-
Sohag, EgyptSohag University Hospital
Sep 14, 2022
CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)
Recruiting
- CML
- Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
-
Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, ArgentinaFUNDALEU
Jun 29, 2023